Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
BBT-176 by Bridge Biotherapeutics for Non-Small Cell Lung Cancer: Likelihood of Approval
BBT-176 is under clinical development by Bridge Biotherapeutics and currently in Phase II for Non-Small Cell Lung Cancer. According to...